{"url":"https://lda.senate.gov/api/v1/filings/f998f33b-26ff-432d-8a6e-bfa2c8144e71/","filing_uuid":"f998f33b-26ff-432d-8a6e-bfa2c8144e71","filing_type":"Q4","filing_type_display":"4th Quarter - Report","filing_year":2019,"filing_period":"fourth_quarter","filing_period_display":"4th Quarter (Oct 1 - Dec 31)","filing_document_url":"https://lda.senate.gov/filings/public/filing/f998f33b-26ff-432d-8a6e-bfa2c8144e71/print/","filing_document_content_type":"text/html","income":"10000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Christopher Moyer","dt_posted":"2020-01-06T09:59:01.590000-05:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"PO Box 762","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Plymouth Meeting","registrant_state":"PA","registrant_zip":"19462","registrant":{"id":401093053,"url":"https://lda.senate.gov/api/v1/registrants/401093053/","house_registrant_id":null,"name":"CHRISTOPHER MOYER","description":"government affairs consulting","address_1":"1020 Doans Way","address_2":null,"address_3":null,"address_4":null,"city":"Blue Bell","state":"PA","state_display":"Pennsylvania","zip":"19422","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CHRISTOPHER MOYER","contact_telephone":"+1 215-906-3173","dt_updated":"2023-07-03T12:25:15.187773-04:00"},"client":{"id":197762,"url":"https://lda.senate.gov/api/v1/clients/197762/","client_id":12,"name":"CAMERON COMPANIES","general_description":"government affairs consulting","client_government_entity":false,"client_self_select":false,"state":"PA","state_display":"Pennsylvania","country":"US","country_display":"United States of America","ppb_state":"PA","ppb_state_display":"Pennsylvania","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2013-07-12"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Monitored the introduction of drug pricing legislation (HR 3) for its potential impact on existing and emerging cancer drug therapies and site neutrality.  Monitored Medicare reimbursement developments in the agencies and Congress for alternative cancer therapies, such as CAR-T.  Reviewed HR 1948, Lymphedema Treatment Act and HR 3235, Access to Genetic Counselor Services Act for potential support.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":58669,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"MOYER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}